Compare OIS & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OIS | OCGN |
|---|---|---|
| Founded | 1995 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 552.6M | 474.8M |
| IPO Year | 2000 | 2014 |
| Metric | OIS | OCGN |
|---|---|---|
| Price | $8.56 | $0.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $14.00 | $9.75 |
| AVG Volume (30 Days) | 447.0K | ★ 6.7M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $1,088,133,000.00 | N/A |
| Revenue This Year | $3.12 | N/A |
| Revenue Next Year | $5.89 | $1,718.38 |
| P/E Ratio | $71.67 | ★ N/A |
| Revenue Growth | ★ 62.26 | N/A |
| 52 Week Low | $5.50 | $1.01 |
| 52 Week High | $14.50 | $2.73 |
| Indicator | OIS | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 49.37 | 29.46 |
| Support Level | $7.97 | N/A |
| Resistance Level | $8.93 | $1.93 |
| Average True Range (ATR) | 0.31 | 0.07 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 52.48 | 4.55 |
Oil States International Inc is a provider of manufactured products and services to customers in the energy, military and industrial sectors. The company operates through three business segments - Offshore Manufactured Products, Completion and Production Services and Downhole Technologies. Its customers include many national oil and natural gas companies, and independent oil and natural gas companies, offshore drilling companies and other oilfield service, defense and industrial companies.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").